Sai Parenteral's (NSE: SAIPARENT) key facts
- Sai Parenteral's Ltd is a diversified pharmaceutical formulations company.
- Sai Parenteral's (NSE: SAIPARENT)’s last known valuation is $185.9M (Apr 2026).
- It has raised $40.3M; the latest was IPO ($43.9M) in Apr 2026.
- Notable investors include Kailas Family Trust, AIG Direct Insurance Services, Arihant Capital Markets, Blue Lotus Capital, Magnifiq Capital Trust — 8 tracked in total.
- Status: Publicly Held.
Who backs Sai Parenteral's (NSE: SAIPARENT)
8- ·Watch Sai Parenteral's (NSE: SAIPARENT): the Monday email on marks, rounds and moves
Sai Parenteral's (NSE: SAIPARENT) funding rounds
No funding rounds for Sai Parenteral's (NSE: SAIPARENT) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Sai Parenteral's (NSE: SAIPARENT) valuation
Sai Parenteral's (NSE: SAIPARENT) is now publicly traded; this page covers its private-market history, where its last recorded valuation was $186 million (Apr 2026). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.
Sai Parenteral's (NSE: SAIPARENT) investors
8 investors are on record for Sai Parenteral's (NSE: SAIPARENT), including Kailas Family Trust, AIG Direct Insurance Services, Arihant Capital Markets and Blue Lotus Capital.
About Sai Parenteral's (NSE: SAIPARENT)
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
- Sector
- Healthcare
- HQ
- Hyderabad, India
- Founded
- 2001
- Employees
- 298
- Website
- saiparenterals.com/
- Ownership
- Publicly Held
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Sai Parenteral's (NSE: SAIPARENT)’s last known valuation, Apr 2026. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.